OlympiA

NCT02032823 📎

Regimen

Experimental
Olaparib 300 mg BID orally for 12 months following completion of local therapy and (neo)adjuvant chemotherapy.
Control
Placebo BID orally for 12 months.

Population

HER2-negative early breast cancer with germline BRCA1/2 pathogenic variant and high risk features (TNBC with node-positive or >=cT2/pT2; HR+/HER2- with >=4 positive nodes or failure to achieve pCR with neoadjuvant therapy + high CPS+EG score). TNBC cohort dominant (~82%).

Key finding

OlympiA established adjuvant olaparib x 1 year for germline BRCA1/2 high-risk HER2-negative early breast cancer (NCCN category 1; FDA approved March 2022). First adjuvant PARP inhibitor to improve both iDFS and OS.

Source: PMID 34081848

Timeline

  • Publication: 2021 Jun 24

Guideline citations

  • NCCN BREAST